Bayer Yaz Patents Are Obvious, Sandoz Tells Fed. Circ.

Law360, Washington (January 8, 2013, 4:04 PM EST) -- Sandoz Inc. and two other generic drugmakers told a Federal Circuit panel on Tuesday that a lower court had erred when it affirmed the validity of Bayer Healthcare Pharmaceuticals Inc.'s Yaz birth control patents, claiming it had overlooked prior art.

While a Nevada federal judge determined the patents-in-suit weren't obvious, Sandoz, Lupin Pharmaceuticals Inc. and Watson Laboratories Inc. maintained that Bayer wasn't the first to suggest a shorter placebo period during a 28-day contraception cycle would decrease the risk of missed-pill pregnancies.

“There is an express...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.